Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16076173 | 0.86 | LMNA (0.53) | ALDH1A1RXFP1USP2GAALMNA | |
| SCHEMBL16122929 | 0.86 | MLKL (0.53) | ALDH1A1RXFP1USP2LMNASMN1; SMN2 | |
| SCHEMBL17609527 | 0.85 | SMN1; SMN2 (0.57) | ALDH1A1RXFP1USP2LMNASMN1; SMN2 | |
| SCHEMBL16076172 | 0.85 | SMN1; SMN2 (0.48) | ALDH1A1RXFP1USP2GAALMNA | |
| SCHEMBL16029375 | 0.85 | MLKL (0.52) | ALDH1A1RXFP1USP2LMNASMN1; SMN2 | |
| SCHEMBL19560319 | 0.85 | MLKL (0.52) | ALDH1A1RXFP1USP2GAALMNA | |
| SCHEMBL16028688 | 0.84 | NPSR1 (0.53) | ALDH1A1RXFP1USP2GAALMNA | |
| SCHEMBL16079030 | 0.81 | SMN1; SMN2 (0.45) | ALDH1A1RXFP1USP2GAALMNA | |
| SCHEMBL638535 | 0.80 | MAPT (0.59) | ALDH1A1USP2GAALMNASMN1; SMN2 | |
| SCHEMBL636243 | 0.79 | LMNA (0.53) | ALDH1A1LMNASMN1; SMN2TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970316-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2970316-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| EP-2970316-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | Hydra Biosciences, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152287-A9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2014152287-A9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2014152287-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152287-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2649045-A2 | SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| EP-2465859-A1 | 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists | Life & Brain GmbH (DE) | 2012-06-20 | — | — | EP | disclosed |
| WO-2012076466-A2 | SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076974-A1 | 8-TRIAZOLYLXANTHINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | LIFE & BRAIN GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | ALDH1A1 1647/4885RXFP1 1171/4885USP2 4322/4885 |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | ALDH1A1 1647/4885RXFP1 1171/4885USP2 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.